A 69-year-old user starting MK-677 shared baseline labs showing low-normal IGF-1 and high Hemoglobin A1c. They expressed concern regarding the peptide’s impact on blood sugar levels, specifically wondering if it would exacerbate their borderline diabetic state. The user intended to monitor labs every two months to track the peptide’s impact on their metabolic health.